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Abstract
Background: The etiologic determinants of stroke in young adults remain a diagnostic challenge in up to
one-fourth of cases. Increasing evidences led to consider Fabry’s disease (FD) as a possible cause to check up.
We aimed at evaluating the prevalence of unrecognized FD in a cohort of patients with juvenile stroke in
northern Sardinia.
Methods: For this study, we enrolled 178 patients consecutively admitted to our Neurological Ward for
ischemic stroke, transient ischemic attack, intracerebral haemorrhage, neuroradiological evidence of silent
infarcts, or white matter lesions possibly related to cerebral vasculopathy at brain MRI, and cerebral venous
thrombosis. The qualifying events have to occur between 18 and 55 years of age.
Results: We identified two patients with an α-galactosidase A gene variant, with a prevalence of 0.9 %.
According to recent diagnostic criteria, one patient, included for the occurrence of multiple white matter
lesions at brain MRI, had a diagnosis of definite FD, the other, included for ischemic stroke, had a diagnosis
of uncertain FD.
Conclusions: Our study places in a middle position among studies that found a prevalence of FD up to
4 % and others that did not find any FD patients. Our findings confirm that FD should be considered in
the differential diagnosis of patients with juvenile stroke, particularly those with a personal or familial
history positive for cerebrovascular events, or evidence of combined cardiologic and/or renal impairment.
All types of cerebrovascular disorders should be screened for FD, including patients with white matter
lesions possibly related to cerebral vasculopathy at brain MRI.
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Background
Stroke is the first leading cause of disability in adults
and the fourth cause of death [1, 2]. In Italy, and other
European countries, there are over 200.000 new cases of
cerebrovascular disorders (CDs) annually, with the
incidence of stroke in young adults peaking at a rate of
ten cases per 100.000 inhabitants [3]. CDs in young
adults are etiologically heterogeneous and the main
clinical challenge in their management remains the iden-
tification of the causes. These may be the result of
shared environmental and genetic factors, leaning to-
ward the hereditary ones in young adults [4]. Single gene
diseases that may present with stroke or transient ische-
mic attack (TIA), include Fabry’s disease (FD) [5], a rare
X-linked inborn error of glycosphingolipids metabolism,
caused by mutations in the alpha-galactosidase A (GLA)
gene, resulting in the reduced production of the enzyme
α-galactosidase A. In FD, the enzymatic deficiency leads
to lysosomal accumulation of neutral glycosphingolipids
in all tissues, particularly in vascular endothelial cells [6].
* Correspondence: gpsechi@uniss.it
1Department of Clinical and Experimental Medicine, University of Sassari,
Viale S. Pietro, 10, 07100 Sassari, Italy
Full list of author information is available at the end of the article
© 2015 Fancellu et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Fancellu et al. BMC Neurology  (2015) 15:256 
DOI 10.1186/s12883-015-0513-z
This is consistent with the natural history of FD that
frequently includes the occurrence of different CDs,
such as TIAs and stroke, even at very young age in both
genders, and the appearance of white matter lesions
(WMLs) on brain MRI due to cerebral vasculopathy [6–9].
Since patients with definite FD may be safely treated
with a specific enzyme replacement therapy (ERT)
with benefit, a timely diagnosis has therapeutic and
prognostic implications [8, 10].
Recently, numerous studies investigating FD preva-
lence in particular populations at risk, such as patients
with juvenile stroke, cryptogenic renal and/or cardiac
disturbances, have been undertaken [11]. In particular,
in the first screening for FD, in patients with juvenile
stroke in Germany, a high number of FD patients (about
4 %) have been detected [12]. However, a subsequent
Belgian study, conducted on a smaller sample of patients
with stroke of unknown origin, was unable to identify
any FD patient [13]. Considering these findings, we
conducted the present, exploratory study to investigate
the prevalence of FD in patients with juvenile stroke in
northern Sardinia, a Mediterranean island, with up to
now unrecognized FD. Judging precedent inclusion
criteria too restrictive, with respect to the CDs qualifying
events (QEs), we considered not only cryptogenic ischemic
stroke but also the other classes of CDs included in the
TOAST classification (Trials of ORG 10172 in Acute
Stroke Syndromes) [14, 15] Moreover, we included
patients with WMLs at brain MRI, possibly related to
cerebral vasculopathy.
Methods
Design of the study
The Exploratory Fabry Cerebrovascular disease Screen-
ing is the first study designed for assessing the occur-
rence of FD in Sardinia. We prospectively analyzed
patients with CDs admitted to our neurological ward, at
Sassari University, in north Sardinia, which allows access
to about 100 patients with CDs per year. Among these
patients, approximately 20 % are people aged between
18 and 55 years of age. People admitted to our neuro-
logical ward come mainly from two north Sardinia areas,
which in 2014 had about 480.000 inhabitants and 260.000
people aged between 18 and 55 years of age (2011
population census, ISTAT findings). Inclusion criteria
were the following: age between 18 and 55 years of age
at the time of the QE, and one of the following QEs,
ischemic stroke (IS), TIA, intracerebral haemorrhage
(ICH), WMLs at brain MRI possibly due to cerebral
vasculopathy, and cerebral venous thrombosis (CVT).
We considered the definition of stroke devised by the
World Health Organization in the 1970s, “neurological
deficit of cerebrovascular cause that persists beyond
24 h” [16]. Considering the multi-tissues involvement
in FD patients, with regard to ischemic stroke we chose
to consider all the other classes of CDs included in the
TOAST classification [14, 15]. Moreover, we included
patients with non-traumatic ICH, defined as every
spontaneous bleeding into the brain [17]; patients with
TIA, defined as an episode with stroke-like symptoms
lasting no more than 24 h, [18] and patients with
WMLs at brain MRI, even in absence of overt clinical
manifestations when possibly due to cerebral vasculop-
athy [19–21]. CVT was defined as a thrombosis in one
or more of cerebral veins.
A diagnosis of definite or uncertain FD was made on
the basis of characteristic phenotypic or biochemical fea-
tures of patients, according to recent diagnostic criteria
for FD in adults [22, 23].
Our primary objective was to estimate the prevalence
of positive DNA mutations or potentially pathogenic
single nucleotide polymorphisms in the GLA gene in an
unselected, consecutive group of patients with one or
more of the chosen QEs. Our secondary objective was to
assess, in each patient, the clinical presentation also in
relation to others associated risk factors for CDs, and to
point out the specific category of the QE, with special
attention to patients with FD, in order to identify
possible clues useful in clinical practice.
Participants and informed consent
All participants enrolled in the study provided written
informed consent for enzymatic and genetic testing,
and for the publication of individual clinical details. A
detailed personal and familiar history, with particular
attention to cerebrovascular risk factors and the
occurrence of signs and symptoms indicative of FD
were noticed. The study protocol was approved by the
Human Ethics Review Committees of Sassari and
Pavia (Prot. N° P-20070030590).
Biochemical studies and genetic analysis
A blood sample on Heparin and on EDTA was drawn
from all patients, and sent to the Molecular Genetics
Laboratory of the Institute of Recovery and Care of
Scientific Character (IRCCS) Foundation “S. Matteo”,
Pavia. Our patients were also integrated into the poly-
centric Italian study GIMAF (Interdisciplinary Group
for Anderson Fabry Disease). Enzyme alpha-galactosidase
A activity was assessed in plasma and leucocytes by spec-
trofluorimetry, considering normal α-galactosidase A level
higher than 2 nmol/mL/h in plasma or 20 nmol/mg prot/
h in leucocytes. DNA analysis was done for each of the
seven exons of GLA gene, amplified by polymerase chain
reaction (PCR). Each PCR product was analyzed by
denaturing high-performance liquid chromatography
(dHPLC), with a sensibility of 66–98 %, searching for het-
eroduplex and was examined amplicons with heteroduplex
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profile by automated DNA sequencing. Concentration of
lyso-Gb3 in plasma was measured by tandem mass spec-
trometry in patients with positive DNA mutations or
potentially pathogenic single nucleotide polymorphisms
in the GLA gene, and in their relatives.
We used the centralized database of the GIMAF
study and a database on our website, including data on
clinical variables.
Results
We identified 187 eligible patients between April 2008
and April 2012. Nine patients were excluded: three pa-
tients because they did not give informed consent, the
others 6 because they did not fulfill the requirements for
definite cerebrovascular events. We included 178 patients
(105 women, and 73 men). The average age at recruitment
was 48.4+/−22.8 years of age, while the mean age at onset
of CDs symptoms was 43.3 years of age (range 20–55
years). The onset of the QE for patients with WMLs refers
to the first documentation of the WMLs at brain MRI.
None of the patients had previous personal or familiar
diagnosis of FD.
Two patients tested positive at the genetic GLA
tests: one man aged 41, included for WMLs, who
showed a known GLA mutation (R227Q), and severe
cardiac and renal involvement, and a woman aged 52,
included for recurrent, cryptogenic ischemic stroke,
who carried the D313Y mutation of GLA gene and
presented with combined cardiac and renal involve-
ment. (Table 1) Moreover, the man had shown acro-
paresthesias since childhood together with frequent
pain crisis, which mainly occurred while doing phys-
ical activity and during fever. Also, at brain MRI, he
showed the pulvinar sign in T1 sequence, and doli-
choectasia of vertebrobasilar artery [24]. The woman,
instead, had a first occurrence of stroke at the age of
48, with the brain MRI showing multiple WMLs. Also,
she had hypertrophic cardiomyopathy and renal damage
with proteinuria and increased serum creatinine. In the
man with the known GLA mutation (R227Q), alpha-
galactosidase A activity was pathologically decreased to
0.5 μmol/l/h (reference, ≥ 2 μmol/l/h) and the concentra-
tion of lyso-Gb3 in plasma was increased to 33.3 ng/ml
(reference, ≤1.8 ng/ml). In the woman carrying the D313Y
variant, instead, alpha-galactosidase A activity was de-
creased in plasma, while the concentration of lyso-Gb3
was within normal limits.
Considering the distribution of QEs: 107 patients pre-
sented IS (59 women and 48 men), 30 TIA, 30 WMLs,
eight ICH and three women CVT. Table 2 shows the
etiopathogenetic TOAST classes we found. Patients
with WMLs came to our attention because of different
neurological disturbances: 11 of them showed gait
disturbances, ten headache, six vertigo and dizziness,
one an epileptic seizure, one an acute confusion state,
one syncopal episodes.
With regard to cardiovascular risk factors, we found a
high percentage of hypertension, (59.5 %) and hyperlipid-
emia (46.6 %), overweight (47.6 %), smoking (24.2 %) and
hyperhomocysteinemia (14 %).
Of note, our FD patients were included in the study on
average 5 years after the qualifying event. During this
time frame, in these patients renal damage progressed
with increase of proteinuria and serum creatinine
We also analyzed 22 relatives (12 women and ten men)
of the two probands. In the first family group, out of 16
relatives examined, two women and three men resulted
affected. In the second family, out of the six relatives
studied, two resulted positive to FD at genetic tests, one
man and one woman. The clinical features of the two
families are shown in Table 3 and the family trees are
presented in Fig. 1.
Discussion
Several studies indicate that patients with FD have a
20-fold increased risk of ischemic stroke and TIA com-
pared to general population [24–26]. Multiple CDs
arising in young and middle-aged adults have been
Table 1 Demographics and risk factors in patients and probands
Demographics Total number FD: R227Q D313Y
Patients 178 1 1
Men 73 (40,7 %) 1 0
Age at recruitment 48,4a 41 52
Age at onset (symptomatic) 43,3a 48
Age at onset (WMLs) 43,5a 41
Risk factors
Hypertension 106 (59,5 %) 1 1
Diabetes 11 (6,1 %) 0 0
Atrial fibrillation 3 (1,7 %) 0 0
Dyslipidemia 83 (46,6 %) 0 1
Smoking 40 (22,4 %) 0 0
Drinking habit 13 (7,3 %) 0 0
Oral contraception 5 (4,7 %) NA 0
Hyperhomocysteine 22 (12,3 %) 1 1
Overweight/obesity 68 (38,2 %) 0 1
Fabry feature
Acroparesthesia 13 (7,3 %) 1 0
Angiokeratoma 0 0 0
Cornea verticillata 1 (0,5 %) 0 0
CKD/Proteinuria 22 (12,3 %) 0 1
Cardiac involvement 32 (17,97 %) 1 1
Abbreviations: FD Fabry’s disease, NA not applicable, amedian NB cornea
verticillata was associated with amiodarone
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Table 2 Fabry diagnosis in the different cerebrovascular diseases
Our study Rolfs 2005 Brouns 2007 Brouns 2010 Wozniak 2010 Baptista 2010 Sarikaya 2012 Marquardt 2012 Dubuc 2012 Rolfs 2013
Sample size 178 721 103 1000 558 493 150 1046 100 5023g
IS 107 (60,1 %) 721 (100 %) 57 (55,3 %) 573 (57.3 %) 1°stroke 558(100 %) 364(73,8 %) 135(90 %) 572(54,6 %) 4a 100(100 %) 3291(65,51 %)
Atherothrombotic 11(10,3 %) 0 0 143 (25,1 %) NR 55(15,1 %) 0 NR / 613(18,6 %)
Cardioembolic 11(10,3 %) 0 0 125 (21,9 %) NR 80 (21,9 %) 0 NR / 549 (16,7 %)
1d; 1a
Lacunar 17(15,8 %) 0 0 99 (17,4 %) NR 98 (26,9 %) 0 NR 13(13 %) 443 (13,5 %)
1d; 1a
Other determined 6(5,6 %) 0 0 69 (12,1 %) NR 27(7,4 %) 0 NR / 585 (17,8 %)
2c 1d
Undetermined 62(57,9 %) 721 57(100 %) 134 (23,5 %) 154 (28 %\) 104(28,5 %) 135 (100 %) NR / 1100 (33,4 %)
1a 32f 1e 1d; 3a
TIA 30(16,8 %) NR 28(27,1 %) 220(22 %) / NR 15 (10 %) 474(45,3 %) / 1071 (22,3 %)
3a 1a
ICH 8(4,5 %) NR 18(17,4 %) 49 (4,9 %) / 115(23,3 %) / / / ICH 271(5,6 %)
1d; 1a CVT/SAH 68 (1,4 %)
CVT 3(1,6 %) / / / / 14(2,8 %) / / /
1d
WMLs 30(16,8 %) / / 153(15,3 %) / 76(15,4 %) / / / /
1b 2a 1d; 2a
Abbreviations: IS ischemic stroke, TIA transient ischemic attack, ICH intracerebral haemorrhage, SAH subarachnoid haemorrhage, CVT cerebral venous thrombosis, WMLs white matter lesions, NR not reported, aD313Y;












described in FD. Stroke is the most frequent, and can
develop either as a consequence of cardiac embolism,
or due to primary cerebral vasculopathy. In patients
with FD, the cerebral vasculopathy is related to damage
in small and large blood vessels, mainly at level of
vertebro-basilar circulation [24, 26]. In a cohort study
of 2446 patients from the Fabry Registry, 138 patients
experienced stroke (about, 5.6 %). Half of these patients
experienced their first stroke before being diagnosed
with FD, and 70 % before any renal or cardiac disturb-
ance [9]. Thus, it is important to search for FD in pa-
tients with early onset CDs. In literature, there is a
wide variability, from 4 to 0 %, in the reported preva-
lence of FD in patients with cryptogenic stroke (Table 2)
[12, 13, 27–32]. This is probably due to different meth-
odological approaches, in particular the choice of dif-
ferent QEs, and the size of the sample analyzed. In our
study, we chose to include several kinds of CDs, as pre-
viously detailed. In other studies, [33, 34] a wide range
of different methods were used, in particular as regards
the choice of QEs. The most recent study on preva-
lence of FD in young adults with CDs comes from the
multinational European study Stroke in Young Fabry
Patients (Sifap) [35]. This study, in a cohort of 5023 pa-
tients, aged between 18 and 55 years, found that the
prevalence of definite FD was 0.5 %, with an adjunctive
0,4 % prevalence for probable FD, including in this def-
inition patients carrying the D313Y variant [36]. In our
study, according to recent diagnostic criteria in adults
[22, 23], comprehensively, we found a 0,9 % prevalence
of FD in young people with CDs, namely, 0,45 % of def-
inite FD, plus 0,45 % of uncertain FD, including the pa-
tient with the D313Y variant genotype.
This is the first study that documents the occurrence
of FD in neurologic patients in Sardinia island. Our
result places in a middle position between the 4 %
prevalence firstly reported in the study by Rolfs [12]
(probably, overestimated), and the studies that found no
FD patients in their clinical records (probably, underesti-
mated) [13, 28]. In our study, two patients with a GLA
gene variant were identified: a man, included for the
occurrence of WMLs possibly due to cerebral vasculopa-
thy at brain MRI, who showed the known GLA mutation
(Arg227Gln), associated with a classical phenotype of
FD. This patient had a profound decrease of alpha-
galactosidase A activity in plasma and leukocytes, and an
Fig. 1 Family trees: Family tree (a) and family tree (b). Probands are indicated by arrows. Patients are numbered as in Table 3
Table 3 Clinical features and enzyme analyses of the Fabry patients
Patients Gender Age at Manifestations α-galactosidase A Lyso-Gb3
(RV: ≥2 μmol/l/h) (RV: ≤1.8 ng/ml)
Diagnosis Acroparesthesia Cerebrovascular Cardiac Renal
P 1a M 41 + WMLs, pulvinar sign Left ventricular
hypertrophy
CKD 0.5 33.3
2a F 51 + - Silent acute
coronary syndrome
- 8.1 5,6
3a M 31 + - - Proteinuria 0.66 31.1
4a M 29 + - Atrial fibrillation - 2 /
5a M 23 + - - - 2 51
6a F 18 + - - - 6.6 4.7
P 7b F 51 - Recurrent stroke and WMLs Left ventricular
hypertrophy
CKD 15.4 2.5
8b M 21 - - - - 2 /
9b F 49 - - - - 5.3 1.3
Abbreviations: P proband; aR227Q, bD313Y, + yes, − no, RV reference values, /,not available
Fancellu et al. BMC Neurology  (2015) 15:256 Page 5 of 7
increased concentration of lyso-Gb3 in plasma; and a
woman, included for recurrent ischemic stroke, who
carried the D313Y GLA gene variant, commonly defined as
polymorphism and reportedly associated with lower alpha-
galactosidase A level in plasma and normal GLA enzyme
activity in leukocytes, causing the so called “pseudodefi-
ciency” [36]. In this woman, the concentration of lyso-Gb3
in plasma was within normal limits. Recently, this mutation,
that was formerly reported as nonpathogenic, has been
associated with multifocal WMLs at brain MRI and exclu-
sive neurologic manifestations [37]. Of note, mono-organic
manifestations have been frequently described with prom-
inent cardiac or renal manifestations in FD [37]. More-
over, several studies reported an association of D313Y
with other typical FD manifestations, such as stroke,
renal failure, peripheral neuropathty, or hypertrophic
cardiomyopathy [27, 33, 38]. In particular, a recent
prospective study including 625 patients with cerebral
ischemia, aged between 18 and 55 years, reported that
this gene variant was associated with cryptogenic
stroke [33]. Notably, the occurrence of a high propor-
tion of FD in recurrent stroke is suggested by our
findings and it has also been reported in the German
and Belgian studies (Table 2) [12, 13, 34, 35].
Moreover, an analysis of studies in literature indicates
that frequent etiologies of ischemic stroke in patients
with FD, according to the TOAST classification, include
the following: cryptogenic, cardioembolic, other deter-
mined and lacunar [12, 13, 27–35]. Interestingly, in litera-
ture, FD diagnosis has been never reported in patients
with atherothrombotic strokes. FD diagnosis, instead, has
also been reported in patients with TIA, ICH, occurrence
of WMLs at brain MRI and CVT. We emphasize the
potential clinical relevance of searching FD in patients
with only WMLs. This is related to the continuing search
for clinical or paraclinical markers useful for an early diag-
nosis in FD patients, and consequently a timely ERT in
definite FD patients [10, 22, 23], with the possibility of
delaying the natural course of the disease.
Sixteen per cent of our patients were included for
WMLs at brain MRI, and we found our first patient in this
group. WMLs are quite common in the elderly general
population, but they are distinctly uncommon among the
general population under 55 years of age [39]. A high
prevalence of WMLs at MRI and silent infarcts were
found in several studies in patients with cerebrovascular
and cardiovascular disorders [39–41]. They have been
found in patients under 49 years of age, in 8 % in the
Framingham Offspring Study and the Helsinki Young
Stroke Registry [41, 42]. Putaala et al. reported a 7 %
prevalence of WMLs in a similar range of age [39]. More-
over, several studies reported a high prevalence of
WMLs in FD patients, reaching 100 % after 55 years
of age [42, 43]. Taken together, these findings indicate
the need for a careful search for FD in this population. Fur-
ther details on the distribution of FD diagnosis in relation
to the inclusion criteria of our patients are reported in
Table 2. Moreover, analyzing cardiovascular risk factors in
our study population, we found a high percentage of hyper-
tension, hyperlipidemia, overweight/obesity and hyperho-
mocysteinemia, in line with other similar screening studies.
Conclusions
Our data indicate the necessity to evaluate FD prevalence
in patients with cerebrovascular disease in young age in
the entire Sardinia island. In particular, the diagnosis of
FD should be considered in patients with cryptogenic
stroke and in patients with WMLs at brain MRI possibly
related to cerebral vasculopathy, especially if other FD
related symptoms are present. Attention should also be
paid to recurrent stroke, which may hide a large propor-
tion of FD patients. In patients at risk, a complete and
detailed personal and family history should be obtained,
together with an accurate search for clinical features
indicative of FD at physical examination. Since FD is now
a potentially treatable clinical condition, an early diagnosis
may have relevant prognostic implications for patients
and their relatives. Neurologists may have a prominent
role in an early identification of this pathology.
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